# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Current 2024 OutlookAs previously disclosed, based on the Company's current business planning and budgeting activities, Pro...
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0....
Stifel analyst Rick Wise upgrades Profound Medical (NASDAQ:PROF) from Hold to Buy and raises the price target from $9 to $12.
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0....
— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings arou...
Alliance Global Partners analyst Ben Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy and lowers the price target ...